Monte Rosa Therapeutics stock rises as TD Cowen reiterates Buy on expanded Novartis deal

Published 15/09/2025, 17:50
Monte Rosa Therapeutics stock rises as TD Cowen reiterates Buy on expanded Novartis deal

Investing.com - TD Cowen has reiterated its Buy rating on Monte Rosa Therapeutics (NASDAQ:GLUE), currently trading at $6.47, following the company’s announcement of an expanded collaboration with Novartis. According to InvestingPro data, analysts see significant upside potential with price targets ranging from $10 to $20, while the company maintains a "GREAT" financial health score.

The expanded deal includes a license for one new immunology and inflammation degrader and options on two additional programs, according to TD Cowen analyst Marc Frahm.

Under the terms of the agreement, Monte Rosa will receive $120 million upfront, option maintenance fees of up to $60 million, and potential milestone payments totaling up to $5.4 billion.

The company will also be eligible for tiered royalties on any products that emerge from the collaboration, though specific royalty rates were not disclosed.

TD Cowen views the expanded deal as validation of Monte Rosa’s QuEEN platform technology for identifying molecular glue degraders, which appears to be a key factor in the firm’s continued Buy recommendation on the stock.

In other recent news, Monte Rosa Therapeutics has announced a significant collaboration with Novartis to develop novel molecular glue degraders for immune-mediated diseases. This agreement provides Monte Rosa with an upfront payment of $120 million and the potential to earn up to $5.7 billion through various milestone payments and royalties. As part of the deal, Novartis gains an exclusive license to an undisclosed discovery target and options to license two programs from Monte Rosa’s preclinical immunology portfolio. Additionally, Monte Rosa has commenced a Phase 1 trial for MRT-8102, a molecular glue degrader targeting NEK7 for inflammatory conditions. This trial includes single and multiple ascending dose cohorts to evaluate safety and other pharmacodynamic markers, with initial results expected in the first half of 2026. These developments mark a notable expansion in Monte Rosa’s research and collaboration efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.